咯咯笑
发表于 2025-3-30 08:27:34
2197-9766 ase classification.New, fully updated edition with several a.The new edition of this well-received book provides a timely update of current knowledge on the biology, disease classification, and treatment of the acute leukemias – acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Th
辩论的终结
发表于 2025-3-30 14:22:35
http://reply.papertrans.cn/15/1444/144380/144380_52.png
变化
发表于 2025-3-30 18:37:02
http://reply.papertrans.cn/15/1444/144380/144380_53.png
IDEAS
发表于 2025-3-30 22:47:16
http://reply.papertrans.cn/15/1444/144380/144380_54.png
dendrites
发表于 2025-3-31 01:05:36
http://reply.papertrans.cn/15/1444/144380/144380_55.png
Meander
发表于 2025-3-31 05:11:32
http://reply.papertrans.cn/15/1444/144380/144380_56.png
RAFF
发表于 2025-3-31 11:09:41
http://reply.papertrans.cn/15/1444/144380/144380_57.png
Tortuous
发表于 2025-3-31 17:00:54
Endogene Sunk Costs und die Kostenstruktur,isease measured at various times in therapy is highly prognostic and may be used to guide therapy. Very high risk patients as well as patients with relapsed or refractory disease may benefit from newer antibody and cell therapies.
Acetabulum
发表于 2025-3-31 19:41:41
https://doi.org/10.1007/978-3-663-04303-4ties such as bispecific T-cell engagers (e.g., blinatumomab), drug conjugate monoclonal antibodies (e.g., inotuzumab ozogamicin), more potent TKIs, and chimeric antigen receptor T-cell therapies are being investigated. In this chapter, we will provide an overview of the current and future treatment paradigms for Ph-positive ALL.
绊住
发表于 2025-3-31 22:02:23
http://reply.papertrans.cn/15/1444/144380/144380_60.png